



ADVANCED INFORMATION

advanced biotech

LATEST NEWS FROM GNOSIS

Gnosis on stage with its ingredients

This autumn we are breathing an intense and vibrant period where successful events have taken place and new key ones are very close.

Our leading ingredients are always on stage in international markets and with the launch of the innovative non-animal Chondroitin Sulfate, Mythocondro[®], the enthusiasm and buzz in the air is contagious as the certainty of instant success. Thanks for making it happen!

Silvia Pisoni
Marketing Manager

Look at...



- Produced by fermentative processes: non-animal production
- High purity and quality profile guaranteed by controlled, reliable and reproducible process
- Suitable for use in conventional foods



vitaMK7[®] and World Osteoporosis Day

Natural vitamin k2 as MK7

Gnosis has participated at the special event "Supplements in the non-pharmacologic treatment of osteoporosis" during the World Osteoporosis Day which takes place every year on October 20th and involves campaigns by national osteoporosis patient societies from around the world with activities in over 90 countries.



The speech held by Prof. Luca Tiano, researcher at the Polytechnic University of Marche (Italy), has described the role of vitamin K2 in the form of menaquinone-7 in bone metabolism. Prof. Tiano, who in 2011 was part of the team that published a study in the British Journal of Nutrition on the enhanced bioavailability of vitamin K2 in olive oil, shows as it may help in reducing the risk of osteoporotic fractures and could be considered a good nutrient for the prevention of osteoporosis.

In particular, he highlighted the benefits of vitaMK7[®], the natural Vitamin K2 obtained through a patented biofermentation process of *Bacillus subtilis* spp natto [US Patent No. 7,718,407] without using potential dangerous solvents and allergens and developed in order to resemble the natural occurring Vitamin K2 present in the Japanese soybean food.

Incoming Events 2016


December 9th - 11th



The Venetian,
Las Vegas - USA
Booth #7037

New study shows significant effect in lowering Homocysteine Serum Levels

A recently published study has investigated the efficacy of Quatrefolic® (400 mcg of Quatrefolic® plus B6, and B12) in lowering homocysteine serum levels (HCys) versus a conventional vitamin supplementation (folic acid + vitamin B) in hypertensive subjects at low cardiovascular risk.




The treatment was significantly effective and the results show a significant HCys reduction in comparison with baseline from 21.5 µmol/L to 10.0 µmol/L with the product containing Quatrefolic® and a reduction against the control group (folic acid + vitamin B).

The ideal HCys level (i.e. less than 10 µmol/L) was reached in 55.8% of cases in the Quatrefolic® group, and it was significantly higher than in controls. No side effects were observed in either treatment group. Homocysteinemia is widely accepted as an independent risk factor for coronary, cerebral and peripheral vascular diseases.

(Mazza et al., Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial. J Biol Regul Homeost Agents. 2016).



1. Ask for your copy of Chondroitin Sulfate and Mythocondro® book at marketing@gnosis-bio.com



2. A brand-new VitaMK7® tool is available! To request a copy, please contact: marketing@gnosis-bio.com

